{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:48:23Z","timestamp":1790279303841,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T00:00:00Z","timestamp":1621987200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["B9991002"],"award-info":[{"award-number":["B9991002"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["B9991003"],"award-info":[{"award-number":["B9991003"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010544","name":"Exelixis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010544","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006293","name":"American Society of Clinical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006293","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013700","name":"National Comprehensive Cancer Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015340","name":"Bayer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.clgc.2021.03.019","type":"journal-article","created":{"date-parts":[[2021,4,4]],"date-time":"2021-04-04T23:49:42Z","timestamp":1617580182000},"page":"e306-e312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Time to Resolution of Axitinib-Related Adverse Events After Treatment Interruption in Patients With Advanced Renal Cell Carcinoma"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2212-080X","authenticated-orcid":false,"given":"Brian I.","family":"Rini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Atkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni K.","family":"Choueiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3788-4623","authenticated-orcid":false,"given":"Despina","family":"Thomaidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Rosbrook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maghull","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Hutson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2021.03.019_bib0001","series-title":"Kidney Cancer version 2","year":"2020"},{"key":"10.1016\/j.clgc.2021.03.019_bib0002","series-title":"eUpdate - renal cell carcinoma treatment recommendations 2","author":"Escudier","year":"2020"},{"key":"10.1016\/j.clgc.2021.03.019_bib0003","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1186\/s40425-019-0813-8","article-title":"The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)","volume":"7","author":"Rini","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clgc.2021.03.019_bib0004","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.clgc.2020.02.012","article-title":"First-line treatment of metastatic renal cell carcinoma in the immuno-oncology era: systematic review and network meta-analysis","volume":"18","author":"Monteiro","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2021.03.019_bib0005","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/COC.0000000000000695","article-title":"Combination therapy for metastatic renal cell carcinoma: a systematic review and network meta-analysis","volume":"43","author":"Alam","year":"2020","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.clgc.2021.03.019_bib0006","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.2147\/DDDT.S109640","article-title":"Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy","volume":"11","author":"Bellesoeur","year":"2017","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.clgc.2021.03.019_bib0007","series-title":"Inlyta\u00ae (axitinib) prescribing information","year":"2020"},{"key":"10.1016\/j.clgc.2021.03.019_bib0008","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s40425-018-0420-0","article-title":"Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study","volume":"6","author":"Amin","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clgc.2021.03.019_bib0009","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1158\/1535-7163.MCT-18-1399","article-title":"Cabozantinib in combination with immunotherapy for advanced renal cell carcinoma and urothelial carcinoma: rationale and clinical evidence","volume":"18","author":"Bergerot","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clgc.2021.03.019_bib0010","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1200\/JCO.2020.38.15_suppl.5008","article-title":"Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1\/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC)","volume":"38","author":"Lee","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2021.03.019_bib0011","doi-asserted-by":"crossref","first-page":"S1142","DOI":"10.1016\/j.annonc.2020.08.2257","article-title":"Nivolumab\u00a0+\u00a0cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: first results from the randomized phase III CheckMate 9ER trial","volume":"31","author":"Choueiri","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2021.03.019_bib0012","series-title":"Nexaver\u00ae (sorafenib) prescribing information","year":"2018"},{"key":"10.1016\/j.clgc.2021.03.019_bib0013","series-title":"Lenvima\u00ae (lenvatinib) prescribing information","year":"2020"},{"key":"10.1016\/j.clgc.2021.03.019_bib0014","series-title":"Cabometyx\u00ae (cabozantinib) prescribing information","year":"2020"},{"key":"10.1016\/j.clgc.2021.03.019_bib0015","series-title":"Sutent\u00ae (sunitinib) prescribing information","year":"2020"},{"key":"10.1016\/j.clgc.2021.03.019_bib0016","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/s41416-020-0949-9","article-title":"Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events","volume":"123","author":"Grunwald","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2021.03.019_bib0017","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2021.03.019_bib0018","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S1470-2045(13)70465-0","article-title":"Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial","volume":"14","author":"Hutson","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2021.03.019_bib0019","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1470-2045(18)30107-4","article-title":"Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial","volume":"19","author":"Choueiri","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2021.03.019_bib0020","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2021.03.019_bib0021","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1470-2045(18)30081-0","article-title":"Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial","volume":"19","author":"Atkins","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2021.03.019_bib0022","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1586\/erp.11.44","article-title":"Cancer-related fatigue: prevalence, assessment and treatment strategies","volume":"11","author":"Weis","year":"2011","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.clgc.2021.03.019_bib0023","first-page":"3353","article-title":"The pathophysiology of cancer-related fatigue: current controversies","volume":"26","author":"O'Higgins","year":"2018","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clgc.2021.03.019_bib0024","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3390\/cells8070738","article-title":"A narrative review of cancer-related fatigue (CRF) and its possible pathogenesis","volume":"8:","author":"Yang","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.clgc.2021.03.019_bib0025","first-page":"e13048","article-title":"Uncertainty and sense-of-self as targets for intervention for cancer-related fatigue","volume":"28","author":"Dolgoy","year":"2019","journal-title":"Eur J Cancer Care (Engl)"},{"key":"10.1016\/j.clgc.2021.03.019_bib0026","doi-asserted-by":"crossref","first-page":"e1412","DOI":"10.1111\/jocn.14245","article-title":"Resilience and positive affect contribute to lower cancer-related fatigue among Chinese patients with gastric cancer","volume":"27","author":"Zou","year":"2018","journal-title":"J Clin Nurs"},{"key":"10.1016\/j.clgc.2021.03.019_bib0027","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/HNP.0000000000000194","article-title":"Exercise interventions to reduce cancer-related fatigue and improve health-related quality of life in cancer patients","volume":"31","author":"Scott","year":"2017","journal-title":"Holist Nurs Pract"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767321000823?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767321000823?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:34:42Z","timestamp":1761564882000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767321000823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S1558767321000823"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2021.03.019","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Time to Resolution of Axitinib-Related Adverse Events After Treatment Interruption in Patients With Advanced Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2021.03.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Pfizer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}